Acumen Pharmaceuticals (ABOS) News Today $1.65 +0.04 (+2.48%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1%January 20 at 3:28 AM | americanbankingnews.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Growth in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 15th total of 1,430,000 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.January 18 at 4:39 AM | marketbeat.comAcumen stock touches 52-week low at $1.54 amid market challengesJanuary 17, 2025 | msn.comAcumen announces Phase 1 INTERCEPT-AD study publicationJanuary 10, 2025 | finance.yahoo.comRussell Barton Sells 7,636 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockJanuary 8, 2025 | insidertrades.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) COO Russell Barton sold 7,636 shares of the business's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.86, for a total value of $14,202.96. Following the transaction, the chief operating officer now owns 89,231 shares in the company, valued at approximately $165,969.66. This trade represents a 7.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider Eric Siemers sold 10,859 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.85, for a total value of $20,089.15. Following the sale, the insider now owns 106,717 shares of the company's stock, valued at $197,426.45. This represents a 9.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 7, 2025 | marketbeat.comMatt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 13,235 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $24,352.40. Following the completion of the transaction, the chief financial officer now owns 198,210 shares of the company's stock, valued at approximately $364,706.40. The trade was a 6.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 47,778 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the transaction, the chief executive officer now owns 454,707 shares in the company, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 5.4% in NovemberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,390,000 shares, a decrease of 5.4% from the November 15th total of 1,470,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 6.9 days. Currently, 3.1% of the shares of the stock are short sold.December 17, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | globenewswire.comHC Wainwright Has Pessimistic View of ABOS FY2024 EarningsAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Acumen Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will pNovember 18, 2024 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,450,000 shares, a growth of 14.2% from the October 15th total of 1,270,000 shares. Approximately 3.2% of the company's stock are short sold. Based on an average daily volume of 184,900 shares, the short-interest ratio is currently 7.8 days.November 16, 2024 | marketbeat.comAcumen Pharmaceuticals Advances Alzheimer’s TherapeuticNovember 14, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)November 14, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comQ3 2024 Acumen Pharmaceuticals Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 13, 2024 | finance.yahoo.comAcumen Pharmaceuticals' Shares Drop on Wider 3Q LossNovember 13, 2024 | marketwatch.comAcumen Pharma Reports Q3 2024, Highlights Alzheimer’s FocusNovember 13, 2024 | markets.businessinsider.comAcumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comAcumen Pharmaceuticals Earnings PreviewNovember 12, 2024 | benzinga.comAcumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNovember 11, 2024 | globenewswire.comAcumen appoints Schacterle as Chief Regulatory Officer, Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNovember 6, 2024 | globenewswire.comAcumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAcumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trialNovember 1, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease ConferenceOctober 31, 2024 | globenewswire.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in OctoberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,270,000 shares, a decline of 18.6% from the September 30th total of 1,560,000 shares. Based on an average trading volume of 203,200 shares, the short-interest ratio is currently 6.3 days. Approximately 2.8% of the shares of the stock are short sold.October 28, 2024 | marketbeat.comAcumen to deliver late-breaking presentation on ACU193 at CTAD conferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 23, 2024 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock, Insider Trading ActivityOctober 21, 2024 | benzinga.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Decline in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,560,000 shares, a drop of 7.7% from the September 15th total of 1,690,000 shares. Approximately 3.5% of the company's shares are short sold. Based on an average trading volume of 254,100 shares, the short-interest ratio is presently 6.1 days.October 16, 2024 | marketbeat.comMillennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Millennium Management LLC lessened its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 25.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,954,085 shares of the company's stock after selling 675,456October 13, 2024 | marketbeat.comRenaissance Technologies LLC Invests $818,000 in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Renaissance Technologies LLC purchased a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 338,100 shares of the company's stock, valued at approximately $818,000. RenOctober 8, 2024 | marketbeat.comBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Sabirnetug Alzheimer’s Treatment DataOctober 4, 2024 | markets.businessinsider.comStrong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193October 4, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Acumen Pharmaceuticals in a research report on Thursday.October 3, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceSeptember 30, 2024 | globenewswire.comAcumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseSeptember 26, 2024 | finance.yahoo.comAcumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024September 25, 2024 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Trading 9.9% Higher Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Up 9.9%September 10, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceSeptember 3, 2024 | globenewswire.comAnalysts Issue Forecasts for Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - HC Wainwright lifted their FY2024 EPS estimates for shares of Acumen Pharmaceuticals in a report issued on Wednesday, August 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($1.01) per share for theAugust 16, 2024 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $6.00UBS Group dropped their target price on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating for the company in a report on Thursday.August 15, 2024 | marketbeat.comBuy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong FinancialsAugust 14, 2024 | markets.businessinsider.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comQ2 2024 Acumen Pharmaceuticals Inc Earnings CallAugust 14, 2024 | finance.yahoo.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.130.44▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼32▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORGO News Today AURA News Today KALV News Today ETON News Today PRME News Today VALN News Today KRRO News Today ENGN News Today GLUE News Today RGNX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
